Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
Journey Medical Corporation to Participate in September 2025 Investor Conferences
H.C. Wainwright 27th Annual Global Investment Conference
Stay informed and receive company updates straight to your inbox.